House Bill 1169:

This bill aims to introduce new requirements for the disclosure of certain products in the state of Missouri. It proposes to amend chapter 196, RSMo, by adding three new sections: 196.1400, 196.1405, and 196.1410. The following layman's explanation provides a breakdown of each section:

Section 196.1400:

This section defines important terms for the purpose of the bill:

1. Cosmetic: This refers to any product applied to the human body, including soap.
2. Food: Refers to any product intended for ingestion.
3. Gene therapy product: Includes any product that has the ability to alter or interfere with genes in any way.
4. Product: Refers to any food, cosmetic, or substance intended to be used on or in the human body, which is available for sale to the general public in Missouri.

The section specifies that any product that has been created to potentially act as gene therapy or has the potential to impact genes must be labeled as a "Potential Gene Therapy Product" unless it is already known to be a gene therapy product. This labeling must be clearly visible to potential purchasers or users of the product.

Section 196.1405:

This section further defines terms and establishes disclosure requirements:

1. Expose: Refers to the transmission of a product to another person through various means such as skin-to-skin contact, sexual activity, or droplets in the air.
2. Genetically modified: Describes the alteration of genetic material through various scientific processes.

If any resident of Missouri requests information about a product that has the capacity to infect or expose individuals to genetically modified material (e.g., vaccines, gene therapies, drugs), the entity responsible for producing, selling, or distributing the product must provide all relevant information regarding potential exposure. This requirement applies to product manufacturers, government agencies, and other organizations involved in the production or distribution of such products.

The entity must fulfill the information request within twenty-one days of receiving the written request from the resident.

Section 196.1410:

This section establishes the requirement for fully informed consent for products that could have any medical intervention, vaccine, drug, or genetic modification impact on individuals in Missouri.

Fully informed consent means that individuals must be informed of all benefits, risks, side effects, adverse events, and other potential impacts of the product before they are exposed to it.

It is important to note that the above explanation is a simplified interpretation of House Bill 1169 and may not capture all details and nuances of the bill.